Loading...
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth
EquityIndex FundsVery High Risk
Direct
NAV (20-Dec-24)
₹19.84-0.87%1D
Returns (Since Inception)
17.95%
Rated ★4.5+ on 
Fund Overview
Fund Size
₹154 Cr
Expense Ratio
0.50%
ISIN
INF754K01LV5
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
About this fund
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth is a Index Funds mutual fund schemes offered by Edelweiss Mutual Fund. This fund has been in existence for 4 years, 1 months and 26 days, having been launched on 26-Oct-20.
As of 20-Dec-24, it has a Net Asset Value (NAV) of ₹19.84, Assets Under Management (AUM) of 153.72 Crores, and an expense ratio of 0.5%.
As of 20-Dec-24, it has a Net Asset Value (NAV) of ₹19.84, Assets Under Management (AUM) of 153.72 Crores, and an expense ratio of 0.5%.
- Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth has given a CAGR return of 17.95% since inception.
- The fund's asset allocation comprises around 99.99% in equities, 0.00% in debts, and 0.01% in cash & cash equivalents.
- You can start investing in Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth with a SIP of ₹100 or a Lumpsum investment of ₹100.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+31.76%
— (Cat Avg.)
3 Years
+16.59%
— (Cat Avg.)
Since Inception
+17.95%
— (Cat Avg.)
Portfolio Summaryas of 30th November 2024
| Equity | ₹153.7 Cr | 99.99% |
| Others | ₹0.01 Cr | 0.01% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹20.9 Cr | 13.34% |
| Cipla Ltd | Equity | ₹9.59 Cr | 6.12% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹9.32 Cr | 5.95% |
| Dr Reddy's Laboratories Ltd | Equity | ₹8.76 Cr | 5.59% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹8.33 Cr | 5.31% |
| Divi's Laboratories Ltd | Equity | ₹8.29 Cr | 5.29% |
| Eli Lilly and Co | Equity | ₹7.97 Cr | 5.09% |
| Lupin Ltd | Equity | ₹5.87 Cr | 3.75% |
| Johnson & Johnson | Equity | ₹4.53 Cr | 2.89% |
| Aurobindo Pharma Ltd | Equity | ₹4.34 Cr | 2.77% |
| Novo Nordisk AS ADR | Equity | ₹4.25 Cr | 2.71% |
| AbbVie Inc | Equity | ₹4.24 Cr | 2.71% |
| Torrent Pharmaceuticals Ltd | Equity | ₹3.83 Cr | 2.44% |
| Fortis Healthcare Ltd | Equity | ₹3.61 Cr | 2.30% |
| Mankind Pharma Ltd | Equity | ₹3.15 Cr | 2.01% |
| Merck & Co Inc | Equity | ₹3.05 Cr | 1.95% |
| Zydus Lifesciences Ltd | Equity | ₹2.97 Cr | 1.89% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.82 Cr | 1.80% |
| Ipca Laboratories Ltd | Equity | ₹2.61 Cr | 1.67% |
| Novartis AG ADR | Equity | ₹2.52 Cr | 1.61% |
| Thermo Fisher Scientific Inc | Equity | ₹2.46 Cr | 1.57% |
| Abbott Laboratories | Equity | ₹2.32 Cr | 1.48% |
| Intuitive Surgical Inc | Equity | ₹2.11 Cr | 1.34% |
| Laurus Labs Ltd | Equity | ₹2.03 Cr | 1.29% |
| Amgen Inc | Equity | ₹2.02 Cr | 1.29% |
| Danaher Corp | Equity | ₹1.93 Cr | 1.23% |
| Syngene International Ltd | Equity | ₹1.84 Cr | 1.17% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹1.61 Cr | 1.03% |
| Ajanta Pharma Ltd | Equity | ₹1.59 Cr | 1.02% |
| Suven Pharmaceuticals Ltd | Equity | ₹1.58 Cr | 1.01% |
| Biocon Ltd | Equity | ₹1.56 Cr | 0.99% |
| Vertex Pharmaceuticals Inc | Equity | ₹1.44 Cr | 0.92% |
| Gland Pharma Ltd | Equity | ₹1.44 Cr | 0.92% |
| Stryker Corp | Equity | ₹1.44 Cr | 0.92% |
| Dr. Lal PathLabs Ltd | Equity | ₹1.38 Cr | 0.88% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.35 Cr | 0.86% |
| Medtronic PLC | Equity | ₹1.35 Cr | 0.86% |
| Gilead Sciences Inc | Equity | ₹1.3 Cr | 0.83% |
| Regeneron Pharmaceuticals Inc | Equity | ₹1.07 Cr | 0.68% |
| Global Health Ltd | Equity | ₹1.05 Cr | 0.67% |
| Pfizer Ltd | Equity | ₹0.82 Cr | 0.53% |
| Becton Dickinson & Co | Equity | ₹0.8 Cr | 0.51% |
| Agilent Technologies Inc | Equity | ₹0.45 Cr | 0.29% |
| IQVIA Holdings Inc | Equity | ₹0.44 Cr | 0.28% |
| Illumina Inc | Equity | ₹0.27 Cr | 0.17% |
| Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹0.1 Cr | 0.06% |
| Net Receivables/(Payables) | Cash - Repurchase Agreement | ₹-0.04 Cr | 0.02% |
| GRAIL Inc | Equity | ₹0 Cr | 0.00% |
| Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
42.10%
Mid Cap Stocks
23.76%
Small Cap Stocks
4.91%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹156.62 Cr | 99.96% |
Risk & Performance Ratios
Standard Deviation
This fund
13.82%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.70
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
BJ
Bhavesh Jain
Since October 2021
Amit Vora
Since February 2021
Additional Scheme Detailsas of 30th November 2024
ISIN INF754K01LV5 | Expense Ratio 0.50% | Exit Load No Charges | Fund Size ₹154 Cr | Age 4 years 1 month | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹585.00 Cr | 28.9% |
| ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹585.00 Cr | 28.2% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹505.89 Cr | 24.6% |
| SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹702.68 Cr | 28.3% |
| DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1895.15 Cr | 13.5% |
| SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1247.77 Cr | 31.6% |
| SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹702.68 Cr | 29.0% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹505.89 Cr | 25.3% |
| DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1895.15 Cr | 14.1% |
| SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1247.77 Cr | 30.8% |
About the AMC
Edelweiss Mutual Fund
Total AUM
₹1,62,281 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Other Funds by Edelweiss Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
The NAV of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth, as of 20-Dec-2024, is ₹19.84.
What are the returns of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
The fund has generated 31.76% over the last 1 year and 16.59% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.
What is the portfolio composition of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
The fund's allocation of assets is distributed as 99.99% in equities, 0.00% in bonds, and 0.01% in cash and cash equivalents.
Who manages the Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
The fund managers responsible for Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth are:-
- Bhavesh Jain
- Amit Vora
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
©2021-2024 Dezerv. All Rights Reserved
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.